Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Vaccines

Green Light for Malaria Vaccine

In July, GlaxoSmithKline’s Mosquirix received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Health. The positive news – and world first – follows nearly 30 years of research and development; the candidate was proposed by GSK scientists in 1987.

The vaccine will be used in sub-Saharan Africa and is cleared for use in children aged 6 weeks to 17 months, with clinical trials showing that it should help offer protection from malaria for at least three years (1). The Phase III trial involved more than 16,000 young children and was conducted by 13 research centers in eight African countries.

But what happens after the three years are up? According to the PATH Malaria Vaccine Initiative, which partnered with GSK to develop the vaccine, a “considerable” amount of work is being done that could, one day, lead to implementation in different age groups (2). In other words, the new vaccine could just be the starting point.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register